4.23
+0.13(+3.17%)
Currency In USD
Address
151 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America
Phone
650 515 3185
Website
Sector
Healthcare
Industry
Biotechnology
Employees
119
First IPO Date
October 08, 2015
| Name | Title | Pay | Year Born |
| Dr. Hoyoung Huh M.D., Ph.D. | Special Advisor to Chief Executive Officer | 72,500 | 1969 |
| Dr. Sean A. McCarthy DPHIL | Chairman & Chief Executive Officer | 680,290 | 1967 |
| Mr. Christopher W. Ogden | SVice President & Chief Financial Officer | 429,652 | 1984 |
| Dr. Yu-Waye Chu M.D. | Chief Medical Officer | 496,938 | 1968 |
| Mr. Lloyd A. Rowland Jr., J.D. | Senior Vice President, General Counsel, Chief Compliance Officer & Secretary | 608,718 | 1957 |
| Dr. Marcia P. Belvin Ph.D. | Senior Vice President & Chief Scientific Officer | 634,827 | N/A |
| Ms. Leslie Robbins | Senior Vice President of Intellectual Property | 0 | N/A |
| Ms. Dawn Benson | Senior Vice President of Quality & Product Manufacturing | 0 | N/A |
| Dr. Stephanie Robertson Ph.D. | Senior Vice President of Alliances & Program Leadership | 0 | N/A |
| Ms. Danielle Olander-Moghadassian | Senior Vice President & Chief Human Resources Officer | 0 | N/A |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.